By Chris Wack
Pasithea Therapeutics shares were up 67% to $3.46 in premarket trading after the company said that an external safety review committee recommended that its Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to cohort 5, 22mg capsule, without modification.
The biotechnology company said that this recommendation was based on the review of the safety data from three patients in cohort 4A, 15mg capsule, and the absence of any dose limiting toxicities.
The Miami company also said that no rash had been observed to date in any of the first 14 patients who have been dosed with PAS-004 in either capsule or tablet formulation. Rash is a common adverse event that is observed at low doses with competitor inhibitors and may lead to the high discontinuation rate in real world practice.
The continuing Phase 1 clinical trial is a multicenter, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, and preliminary efficacy of PAS-004 in patients with advanced solid tumors.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 05, 2025 09:04 ET (14:04 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。